ProPhase Labs, Inc.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US74345W1080

USD

0.14

0 (-0.71%)

Dec 04

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Chromadex Corp.

Nature's Sunshine Products, Inc.

LifeVantage Corp.

Upexi, Inc.

Natural Alternatives International, Inc.

ProPhase Labs, Inc.

USANA Health Sciences, Inc.

Revolution Medicines, Inc.

Cidara Therapeutics, Inc.

MIRA Pharmaceuticals, Inc.

Bright Green Corp.

Why is ProPhase Labs, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate -239.57% of over the last 5 years

Flat results in Jun 25

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -75.85%, its profits have fallen by -38.6%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -75.85% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ProPhase Labs, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

ProPhase Labs, Inc.

-81.96%

-0.67

144.16%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-2.56%

EBIT Growth (5y)

-239.57%

EBIT to Interest (avg)

0.30

Debt to EBITDA (avg)

Net Debt to Equity (avg)

0.48

Sales to Capital Employed (avg)

0.79

Tax Ratio

23.71%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

20.59%

ROCE (avg)

13.43%

ROE (avg)

9.38%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.25

EV to EBIT

-0.98

EV to EBITDA

-1.35

EV to Capital Employed

1.17

EV to Sales

2.53

PEG Ratio

Dividend Yield

ROCE (Latest)

-119.77%

ROE (Latest)

-149.07%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -611.58% (YoY

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for ProPhase Labs, Inc.

Raw Material Cost

Fallen by -611.58% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales